Precision medicine in head & neck cancer: the rise of ADCs and targeted agents
Description
In this week’s podcast from VJOncology, three leading experts provide insights into the latest advances in precision medicine for head and neck cancer.
Luigi Lorini of Humanitas Research Hospital discusses the evolving treatment landscape of immunotherapy in head and neck squamous cell carcinoma. Danny Rischin of the Peter MacCallum Cancer Centre presents findings from a Phase II trial evaluating fianlimab plus cemiplimab in patients with recurrent or metastatic PD-L1–expressing head and neck squamous cell carcinoma. Finally, Jun Ma from Sun Yat-sen University Cancer Center explores the future of immunotherapy in nasopharyngeal carcinoma beyond PD-1 and shares results from the Phase III DIAMOND trial of toripalimab with induction chemotherapy and radiotherapy, with or without concurrent cisplatin, in locoregionally advanced disease.
United States
